Oral Presentations
Atopic Dermatitis
Atopic Dermatitis and Life Course Disruption: Evidence From a Multidimensional International Survey (TOPiQAL)
(Session: Free Communication 1: Atopic dermatitis/Eczema. Thursday, October 1, 2:50-3:00 a.m. ET [8:50-9:00 a.m. CEST]. Abstract #FC01.1C)
Poster Presentations
Atopic Dermatitis
Comparative Efficacy of 1.5% Ruxolitinib Cream Versus Systemic Therapies in Moderate Atopic Dermatitis
(Session: Atopic dermatitis/Eczema - Part II. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P0196.)
Long-Term Safety and Pharmacokinetics of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis Eligible for Systemic Therapy: 24-Week Results From the TRuE-AD4 Study
(Session: Atopic dermatitis/Eczema - Part III. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1544.)
Patient Profile and Multidimensional Burden of Atopic Dermatitis: Results From an International Survey (TOPiQAL)
(Session: Atopic dermatitis/Eczema - Part III. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1543.)
Patient Treatment Preferences in Atopic Dermatitis: Best–Worst Scaling Results From an International Study (TOPiQAL)
(Session: Atopic dermatitis/Eczema - Part III. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1615.)
Ruxolitinib Cream in Moderate Atopic Dermatitis Across Disease Severity Thresholds: Insights From Randomized Trials and Real-World Data
(Session: Atopic dermatitis/Eczema Part - III. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1617.)
Ruxolitinib Cream Maintains Improvements in Patient-Reported Symptom and Quality of Life Outcomes When Used As Needed in Adults With Moderate Atopic Dermatitis Eligible for Systemic Therapy: Long-Term Results From the TRuE-AD4 Study
(Session: Atopic dermatitis/Eczema - Part III. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1618.)
Ruxolitinib Cream Reduced High Symptom and Quality-of-Life Burden in Adults With Moderate Atopic Dermatitis After Failure of Topical Corticosteroids and Topical Calcineurin Inhibitors: Item-Level Patient-Reported Outcome Results From TRuE-AD4
(Session: Atopic dermatitis/Eczema - Part III. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1547.)
Ruxolitinib Cream Use to Delay or Prevent Treatment Escalation in Adults With Moderate Atopic Dermatitis Eligible for Systemic Therapy: Results From the TRuE-AD4 Study
(Session: Atopic dermatitis/Eczema - Part III. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1614.)
Hidradenitis Suppurativa
Characterization of Acne in Pooled STOP-HS1/STOP-HS2 Phase 3 Studies of Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa
(Session: Acne and related disorders, hidradenitis suppurativa - Part II. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1374.)
Effect of Povorcitinib on Clinical, Patient-Reported, and Biomarker Outcomes in Patients With High Disease Burden: Results of Pooled STOP-HS1/STOP-HS2 Phase 3 Studies in Hidradenitis Suppurativa
(Session: Acne and related disorders, hidradenitis suppurativa - Part II. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1343.)
Real-World Treatment Challenges and Unmet Needs in Biologic-Experienced European Patients With Hidradenitis Suppurativa: Insights From the HERALD Survey
(Session: Acne and related disorders, hidradenitis suppurativa - Part II. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1394.)
Prurigo Nodularis
A Real-World, Claims-Based Algorithm for Identifying Moderate to Severe Prurigo Nodularis
(Session: Inflammatory skin diseases - Part II. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P2314.)
Incidence, Prevalence, Treatment Patterns, and Healthcare Resource Utilization of Prurigo Nodularis in the US and Germany
(Session: Inflammatory skin diseases - Part II. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P2279.)
Vitiligo
Application of Exposure-Response Modeling to Inform the Phase 3 Dose Selection of Povorcitinib in Nonsegmental Vitiligo
(Session: Biologics, immunotherapy, targeted therapy. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P1780.)
Development of a Prospective, Regulatory-Grade Disease Registry to Characterize Real-World Nonsegmental Vitiligo Care
(Session: Pigmentary disorders. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P2463.)
Quality-of-Life Impairment and Impact of Treatment in an Open-Label, Phase 2 Study of Ruxolitinib Cream in Patients With Genital Vitiligo
(Session: Pigmentary disorders. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P2467.)
General
Integrated Mixed-Effects Analysis of Pharmacokinetics of Ruxolitinib Cream and Implications on Safety Profile in Patients With Inflammatory Skin Diseases
(Session: Inflammatory skin diseases - Part II. Wednesday, September 30, 1:00 a.m. ET [7:00 a.m. CEST]. Abstract #P2288.)